Karyopharm to Participate at Upcoming Investor Conferences
Get Alerts KPTI Hot Sheet
Join SI Premium – FREE
Format: Podium presentation
Date:
Time:
Morgan Stanley 21st Annual Global Healthcare Conference
Format: Fireside chat
Date:
Time:
Baird 2023 Global Healthcare Conference
Format: Fireside chat
Date:
Time:
A live webcast of the presentation and fireside chats, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following each presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-301918139.html
SOURCE Karyopharm Therapeutics Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Back to School with Zum: The Most Important Commute in America Begins Again
- Eylsia Nicolas Continues Her Global Surge: New BookKard Release, Power Ace Radio Honors, and a Life Story Spanning Tennis Triumphs, Hollywood Turbulence, Academic Leadership, Patented Sound Technology
- Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in July
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Morgan Stanley, Robert W Baird, Twitter, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share